Background Mobile health programs (MHPs) provide essential preventive services to uninsured and underserved communities. Following the 2024 regulatory approval of human papillomavirus (HPV) self-collection for cervical cancer screening, MHPs represent an access point for healthcare-based self-collection. However, little is known about patient perceptions of this approach in MHP and other healthcare settings.

Methods From May – August 2025, we surveyed individuals aged 25–65 years with a cervix who attended MHPs in Southern Arizona. The survey assessed interest in HPV self-collection, preferred locations, instructional preferences, and facilitators to attend follow-up after a positive result. Descriptive statistics summarized demographic characteristics and survey responses.

Results Fifteen female participants completed the survey (mean age 36 years). Ten (67%) identified as Hispanic or Latino, nine (60%) preferred Spanish, and 14 (93%) were uninsured. Interest in HPV self-collection was high, with ten (67%) very or extremely interested. Among those interested, nine (69%) preferred home-based self-collection, and four (31%) preferred clinic or MHP-based self-collection. Most common concerns regarding self-collection on the MHP were ensuring privacy (n=7; 47%) and knowing how to perform the test correctly (n=5; 33%). Most participants (n=11; 73%) reported being very or extremely confident they would attend follow-up after a positive result; language-concordant support, reminder calls, and scheduling assistance were the most endorsed facilitators.

Conclusion HPV self-collection was highly acceptable among MHP attendees, although home-based self-collection was most preferred. Addressing privacy concerns, providing multiple modes of instruction, and offering navigation support may improve implementation success and ensure timely follow-up care in MHP settings.

The authors have declared no competing interest.

Dr. Morenz is supported by the K12 Program at the Southwest Center for Advancing Clinical and Translational Innovation, funded by the National Center for Advancing Translational Sciences under Award Number K12TR005467. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of Arizona Institutional Review Board reviewed and approved this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors and completion of a data use agreement.